| Literature DB >> 30358849 |
Christian Pristipino1, Horst Sievert2,3, Fabrizio D'Ascenzo4, Jean Louis Mas5, Bernhard Meier6, Paolo Scacciatella4, David Hildick-Smith7, Fiorenzo Gaita4, Danilo Toni8, Paul Kyrle9, John Thomson10, Genevieve Derumeaux11, Eustaquio Onorato12, Dirk Sibbing13, Peter Germonpré14, Sergio Berti15, Massimo Chessa16, Francesco Bedogni16, Dariusz Dudek17, Marius Hornung2, Jose Zamorano18.
Abstract
The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have been published. This interdisciplinary paper, prepared with involvement of eight European scientific societies, aims to review the available trial evidence and to define the principles needed to guide decision making in patients with PFO. In order to guarantee a strict process, position statements were developed with the use of a modified grading of recommendations assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements of particular management options were weighed and graded according to predefined scales. Despite being based often on limited and non-randomised data, while waiting for more conclusive evidence, it was possible to conclude on a number of position statements regarding a rational general approach to PFO management and to specific considerations regarding left circulation thromboembolism. For some therapeutic aspects, it was possible to express stricter position statements based on randomised trials. This position paper provides the first largely shared, interdisciplinary approach for a rational PFO management based on the best available evidence. The article has been co-published with permission in the European Heart Journal and EuroIntervention. All rights reserved.Entities:
Mesh:
Year: 2019 PMID: 30358849 DOI: 10.1093/eurheartj/ehy649
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983